Introduction: Cancer pain is one of the most prevalent manageable symptoms in patients with advanced cancer, and it has a negative impact on quality of life (QoL).
Objective: The aim of this study is to examine the correlation between cancer pain and QoL in patients with advanced cancer who are hospitalized in a palliative care unit.
Methods: This study is a cross-sectional analysis of patients with advanced cancer who were hospitalized with cancer pain at a specialized palliative care unit between June 2021 and February 2022. Pain intensity and its impact on daily activities were assessed using the Brief Pain Inventory (BPI), while the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Core 15 PAL (QLQ-C15-PAL) was used to evaluate QoL.
Results: A total of 104 patients with cancer pain were included, with a mean age of 53.6 years (±14.1). Most of the patients were female (65.38%), and the most common primary tumor site was in the gastrointestinal tract (22.11%). The most frequently reported site of cancer pain was the abdomen (32.69%). The mean duration of cancer pain was 52.3 days (±6.2). The domains of QoL most strongly correlated with cancer pain were weakness (coefficient = .52, < .001), nausea (coefficient = .36, < .001), and the physical domain (coefficient = -.30, < .001).
Conclusion: Cancer pain is strongly correlated with a deterioration in QoL in patients with advanced cancer, and its management should be pursued as a strategy for optimizing QoL.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1177/10499091231195318 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
First-in-human, multicenter, open-label, phase I study of ATOR-1017 (evunzekibart), a 4-1BB antibody, in patients with advanced solid malignancies.
J Immunother Cancer
January 2025
Department of Oncology, Uppsala University Hospital, Uppsala, Sweden
Background: ATOR-1017 (evunzekibart) is a human agonistic immunoglobulin G4 antibody targeting the costimulatory receptor 4-1BB (CD137). ATOR-1017 activates T cells and natural killer cells in the tumor environment, leading to immune-mediated tumor cell death.
Methods: In this first-in-human, multicenter, phase I study, ATOR-1017 was administered intravenously every 21 days as a monotherapy to patients with advanced, unresectable solid tumors having received multiple standard-of-care treatments.
Quality of Life and Social Health in Patients After Pancreatic Surgery.
J Gastrointest Surg
January 2025
Department of Surgery, University of Arizona, Tucson, AZ. Electronic address:
Background: Clinicians lack robust data on quality of life and social functioning after pancreatectomy limiting their ability guide patient decision-making aligned with patients' goals of care.
Methods: In this cross-sectional survey study, we administered the European Organization for Research and Treatment of Cancer Core Quality of Life questionnaire (EORTC QLQ-C30); pancreas-specific QLQ-PAN26; Patient-Reported Outcomes Measurement Information System (PROMIS™) Ability to Participate in Social Roles; and PROMIS™ Activities and social Isolation scales to all elective pancreatectomies (2021-2023). Results were compared to both normative data and between groups to determine factors predicting better QOL with a >10-12-point change considered clinically significant.
Effect of perioperative analgesia on immunity in lung cancer.
Immunobiology
January 2025
Department of Anesthesiology, The Third Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China. Electronic address:
COX inhibitors are frequently used for pain management during the perioperative period and may influence tumor progression and the tumor microenvironment by modulating inflammation and immune responses. This study investigates the effects of COX inhibitors on tumor growth and the immune microenvironment. In vivo experiments demonstrate that COX inhibitors can reduce tumor cell growth, elevate PD-L1 expression on tumor cells, and enhance the proportion of myeloid cells within the tumor immune microenvironment.
View Article and Find Full Text PDFThe impact of adverse childhood experiences on pain and subjective cognitive decline in patients treated for localized breast cancer: The mediating role of sense of coherence, sense of danger and psychosocial distress and danger.
Breast
January 2025
Oncology Division, Rambam Health Care Campus, HaAliya HaShniya St 8, Haifa, 3109601, Israel; Bruce Rappaport Faculty of Medicine, Technion Israeli Institute of Technology, Efron St 1, Haifa, 3525433, Israel. Electronic address:
Background: Pain and subjective cognitive decline (SCD) are common sequala of breast cancer (BC) treatment. Adverse childhood experiences (ACEs) are associated with pain and adverse health outcomes in noncancer population. Sense of coherence (SOC) reflects the disposition that life is manageable and predictable.
View Article and Find Full Text PDFEffects of individualized nurse-led care plans on olaparib treatment duration.
Am J Manag Care
January 2025
Arine, 595 Market St #2550, San Francisco, CA 94105. Email:
Objective: To assess the effects of a nurse-led personalized care plan on the duration of olaparib therapy among patients with cancer.
Study Design: Cohort study conducted from January 2020 to June 2022.
Methods: Data from an independent specialty pharmacy were used to identify patients 18 years and older with at least 1 olaparib (Lynparza) prescription who were at high risk for olaparib nonadherence as assessed using a pharmacy intake survey.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!